Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation.

@article{Einsele2006OralVL,
  title={Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation.},
  author={Hermann Einsele and Pierre Reusser and Martin Bornhaeuser and Peter Kalhs and Gerhard Ehninger and Holger F. Hebart and Yves Chalandon and Nicolaus Kr{\"o}ger and Bernd Hertenstein and Frank Rohde},
  journal={Blood},
  year={2006},
  volume={107 7},
  pages={3002-8}
}
Cytomegalovirus (CMV) infection is a major complication after allogeneic stem cell transplantation (SCT). Valganciclovir (V-GCV) is an oral prodrug hydrolyzed to the anti-CMV drug ganciclovir (GCV). A randomized, multicenter, crossover, open-label clinical trial compared exposure to GCV after V-GCV and intravenous GCV (IV-GCV) as preemptive therapy for CMV disease in SCT. The primary objective was to compare exposure to GCV in patients with CMV infection stratified for intestinal graft-versus… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

Similar Papers

Loading similar papers…